BERKELEY, CA (UroToday.com) - Docetaxel has been widely accepted as a first-choice chemotherapeutic agent for managing castration resistant prostate cancer (CRPC). The main side effects of docetaxel are neutropenia, hypersensitivity reaction, stomatitis, peripheral neuropathy and fluid retention.[1] Interstitial pneumonitis is a rare adverse effect but the mortality rate is high, thus the awareness of this toxicity is important. Herein, we report a patient with acute life-threatening interstitial pneumonitis after docetaxel therapy.